

Alessandro Rizzo

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/4912847/publications.pdf](https://exaly.com/author-pdf/4912847/publications.pdf)

Version: 2025-02-01

124

PR articles

4,597

PR citations

42634

43

PR h-index

89639

63

g-index

178

documents

6161

doc citations

29041

52

h-index

4776

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Lifestyle Profiles of Italian Oncology Nurses according to Sex, Work Experience and Shift: An Exploratory Study. <i>Diseases (Basel, Switzerland)</i> , 2024, 12, 58.	2.8	1
2	Associations between "Cancer Risk", "Inflammation" and "Metabolic Syndrome": A Scoping Review. <i>Biology</i> , 2024, 13, 352.	2.9	68
3	Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2024, 16, 1835.	4.0	145
4	Autotaxin "Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2024, 25, 7737.	4.5	15
5	Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project. <i>Targeted Oncology</i> , 2024, 19, 747-755.	3.3	4
6	Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes. <i>Future Oncology</i> , 2024, 20, 1427-1434.	2.4	6
7	Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications. <i>Cancers</i> , 2024, 16, 3542.	4.0	9
8	Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2024, 16, 3689.	4.0	136
9	Lean Perspectives in an Organizational Change in a Scientific Direction of an Italian Research Institute: Experience of the Cancer Institute of Bari. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 239.	3.1	2
10	Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. <i>Current Oncology</i> , 2023, 30, 749-757.	3.1	7
11	Bayesian analysis supports the role of alectinib and ensartinib for <sc>ALK</sc> "positive non" small cell lung cancer. <i>Thoracic Cancer</i> , 2023, , .	2.0	0
12	Hypertransaminasemia in Metastatic Renal Cell Carcinoma Patients Receiving Immune-Based Combinations: A Meta-Analysis. <i>Immunotherapy</i> , 2023, 15, 117-126.	2.1	3
13	Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta-analysis of randomized controlled trials. <i>Thoracic Cancer</i> , 2023, 14, 1029-1035.	2.0	6
14	A Machine Learning Approach for Predicting Capsular Contracture after Postmastectomy Radiotherapy in Breast Cancer Patients. <i>Healthcare (Switzerland)</i> , 2023, 11, 1042.	2.3	5
15	Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues. <i>Cancers</i> , 2023, 15, 2376.	4.0	8
16	Human Adult Renal Progenitor Cells Prevent Cisplatin-Nephrotoxicity by Inducing CYP1B1 Overexpression and miR-27b-3p Down-Regulation through Extracellular Vesicles. <i>Cells</i> , 2023, 12, 1655.	4.8	11
17	The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma. <i>Current Oncology</i> , 2023, 30, 4754-4766.	3.1	2
18	Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis. <i>Cancer Treatment and Research Communications</i> , 2023, 37, 100775.	1.8	4

#	ARTICLE	IF	PR CITATIONS
19	Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2-positive breast cancer patients: A machine learning approach. <i>Cancer Medicine</i> , 2023, 12, 20663-20669.	2.7	5
20	Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 152-159.	3.6	75
21	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. <i>European Urology Focus</i> , 2022, 8, 514-521.	3.6	80
22	PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 415-423.	4.0	92
23	Microbiota and prostate cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 1058-1065.	14.1	92
24	Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 557-565.	4.0	81
25	Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 549-555.	4.0	124
26	Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 361-369.	4.0	85
27	Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. <i>Current Oncology</i> , 2022, 29, 551-564.	3.1	8
28	Chemoimmunotherapy versus immune checkpoint inhibitors monotherapy as first-line treatment for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, , .	2.0	1
29	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. <i>Future Oncology</i> , 2022, 18, 739-748.	2.4	16
30	Dual Immune Checkpoint Blockade in Hepatocellular Carcinoma: Where do we Stand?. <i>Future Oncology</i> , 2022, 18, 1023-1034.	2.4	6
31	Risk of Toxicity with Immunotherapy-Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials. <i>Future Oncology</i> , 2022, 18, 625-634.	2.4	9
32	Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1038.	2.6	3
33	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. <i>European Urology Focus</i> , 2022, 8, 1696-1702.	3.6	32
34	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 285-295.	2.4	7
35	Radiofrequency ablation, radiation therapy, transarterial chemoembolization, and yttrium 90: no differences for local treatment of liver cancer?. <i>Acta Oncologica</i> , 2022, 61, 730-730.	1.8	3
36	Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 1404.	4.0	88

#	ARTICLE	IF	PR CITATIONS
37	KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. <i>Future Oncology</i> , 2022, 18, 2301-2309.	2.4	85
38	Assessing Pd-L1 Status in Mrcc Treated with First-Line Immune-Based Combinations: A Meta-Analysis. <i>Immunotherapy</i> , 2022, 14, 617-625.	2.1	3
39	Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 333-339.	2.5	75
40	An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients' Age: A Retrospective Cohort Study. <i>Cancers</i> , 2022, 14, 2215.	4.0	5
41	Genomics and Immunomics in the Treatment of Urothelial Carcinoma. <i>Current Oncology</i> , 2022, 29, 3499-3518.	3.1	9
42	Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. <i>Cancers</i> , 2022, 14, 2429.	4.0	93
43	Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 707-713.	4.0	3
44	The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 842.	2.6	14
45	Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. <i>Cells</i> , 2022, 11, 1857.	4.8	19
46	Letter re: "Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review and Bayesian network meta-analysis" <i>European Journal of Cancer</i> , 2022, 174, 321-322.	5.1	0
47	Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center. <i>Current Oncology</i> , 2022, 29, 5084-5090.	3.1	5
48	Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4373.	2.6	5
49	Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1247.	2.6	9
50	Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer. <i>Thoracic Cancer</i> , 2022, , .	2.0	2
51	Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine. <i>Translational Oncology</i> , 2022, 25, 101514.	3.7	21
52	Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. <i>Cancers</i> , 2022, 14, 4142.	4.0	26
53	Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma. <i>Oncologist</i> , 2022, , .	3.5	2
54	Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 177, 175-185.	5.1	144

#	ARTICLE	IF	PR CITATIONS
55	Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. <i>Medicina (Lithuania)</i> , 2022, 58, 1543.	2.2	5
56	The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 10548.	2.2	7
57	Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 317-324.	4.0	84
58	Recent advances of immunotherapy for biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 527-536.	2.5	111
59	Experimental HER2- targeted therapies for biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 389-399.	4.0	13
60	Immortal Time Bias in the Association Between Toxicity and Response for Immune Checkpoint Inhibitors: A Meta-Analysis. <i>Immunotherapy</i> , 2021, 13, 257-270.	2.1	120
61	Nivolumab: an investigational agent for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 325-332.	4.0	9
62	BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 483-485.	2.5	66
63	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100328.	1.8	83
64	First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!” <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100335.	1.8	71
65	Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100354.	1.8	76
66	Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100337.	1.8	63
67	Targeted therapy in SDH-deficient GIST. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, .	3.8	33
68	PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. <i>Cancers</i> , 2021, 13, 558.	4.0	243
69	In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)” <i>Oncologist</i> , 2021, 26, e902-e902.	3.5	6
70	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1551.	4.5	87
71	Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 547-554.	2.5	77
72	Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1057.	2.6	22

#	ARTICLE	IF	PR CITATIONS
73	Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing. <i>Pathology Research and Practice</i> , 2021, 219, 153350.	3.0	5
74	Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 343-350.	4.0	91
75	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?â€”a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1541-1552.	1.3	11
76	FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 567-574.	2.5	9
77	Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. <i>Pathology Research and Practice</i> , 2021, 220, 153410.	3.0	3
78	Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 217-224.	0.9	0
79	Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3805.	4.5	142
80	Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. <i>Medicina (Lithuania)</i> , 2021, 57, 458.	2.2	13
81	Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait. <i>Immunotherapy</i> , 2021, 13, 637-644.	2.1	77
82	Comparative Effectiveness of First-Line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors According to IMDCâ€™Risk Groups in Metastatic Renal Cell Carcinoma: A Meta-Analysis. <i>Immunotherapy</i> , 2021, 13, 783-793.	2.1	5
83	Determinants of Treatment for First-Line Immune-Based Combinations in Metastatic Renal Cell Carcinoma: a Critical Overview of Recent Evidence. <i>Immunotherapy</i> , 2021, 13, 685-692.	2.1	8
84	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: Whatâ€™s the Story Morning Glory?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6237.	4.5	32
85	Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. <i>Pathology Research and Practice</i> , 2021, 222, 153440.	3.0	14
86	Quality of Life Assessment in Renal Cell Carcinoma Phase II and III Clinical Trials Published between 2010 and 2020: a Systematic Review. <i>Future Oncology</i> , 2021, 17, 2671-2681.	2.4	29
87	Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. <i>Pharmaceuticals</i> , 2021, 14, 677.	4.4	49
88	An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2323-2336.	2.2	4
89	Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 154, 120-127.	5.1	88
90	Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. <i>Current Oncology</i> , 2021, 28, 3393-3402.	3.1	59

#	ARTICLE	IF	PR CITATIONS
91	IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100356.	1.8	27
92	Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 5.	1.8	3
93	Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100334.	1.8	14
94	Optimizing outcomes in HCC: Comment on "Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis" by Jiang et al.. <i>Translational Oncology</i> , 2021, 14, 101246.	3.7	0
95	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13519.	4.5	24
96	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. <i>Frontiers in Oncology</i> , 2021, 11, .	2.7	93
97	Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2021, 17, 61-68.	3.3	73
98	Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis. <i>Future Oncology</i> , 2020, 16, 4409-4418.	2.4	71
99	Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer". <i>Oncologist</i> , 2020, 25, e1818-e1818.	3.5	5
100	Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. <i>Cancer Genetics</i> , 2020, 248-249, 57-62.	0.6	16
101	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103119.	5.2	124
102	Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, .	3.8	93
103	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 755-763.	2.6	15
104	Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis. <i>Cancers</i> , 2020, 12, 1899.	4.0	50
105	Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. <i>Cancers</i> , 2020, 12, 2126.	4.0	81
106	Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 441-452.	1.7	94
107	PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 54.	1.8	30
108	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020, 9, 2051.	4.8	79

#	ARTICLE	IF	PR CITATIONS
109	Evolution of the Experimental Models of Cholangiocarcinoma. <i>Cancers</i> , 2020, 12, 2308.	4.0	92
110	Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. <i>Cancers</i> , 2020, 12, 3256.	4.0	11
111	The (Eternal) Debate on Microwave Ablation <i>versus</i> Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. <i>In Vivo</i> , 2020, 34, 3421-3429.	1.3	16
112	Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. <i>International Journal of Hyperthermia</i> , 2020, 37, 479-485.	2.6	68
113	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 491-501.	2.6	18
114	Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow. <i>Anticancer Research</i> , 2020, 40, 3013-3030.	1.2	73
115	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	4.0	89
116	Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art. <i>Anticancer Research</i> , 2020, 40, 1229-1238.	1.2	34
117	How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020, 34, 1701-1714.	1.3	35
118	Specific Toxicity of Maintenance Olaparib <i>versus</i> Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis. <i>Anticancer Research</i> , 2020, 40, 597-608.	1.2	26
119	Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020, 34, 479-488.	1.3	78
120	Pancreatic mucinous cystadenocarcinoma in a patient harbouring <i>BRCA1</i> germline mutation effectively treated with olaparib: A case report. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 1456-1463.	2.2	3
121	Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. <i>Cancer Control</i> , 2020, 27, .	2.4	33
122	Granular cell tumor of the trachea as a rare cause of dyspnea in a young woman. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100961.	0.3	4
123	Current status of the adjuvant therapy in uterine sarcoma: A literature review. <i>World Journal of Clinical Cases</i> , 2019, 7, 1753-1763.	1.1	60
124	Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. <i>Scientific Reports</i> , 2018, 8, .	3.5	94